By Administrator_India
The Centre placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine Covishield’, each costing Rs 210, including GST, sources said.
The HLL Lifecare Limited, a public sector undertaking, on behalf of the Union health ministry issued the supply order in the name of Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), Pune.
The government had on January 11 also committed to buy from the Serum Institute 4.5 crore doses of the vaccine, in addition to the first order of 1.1 crore doses.
India has approved two COVID-19 vaccines–Covishield manufactured by SII and indigenously developed Covaxin of Bharat Biotech–for restricted emergency use in the country.
On Tuesday, the capital markets regulator Sebi fined nine organizations a total of Rs 1.62 crore for manipulating Sterling Green Read more
In May of this year, India's palm oil imports fell by 33.20 percent to Rs 5,14,022 tonnes, while refineries sent Read more
According to statistics published on Friday by the Union Health Ministry, India's COVID-19 case count grew by 7,584 in a Read more
Maharashtra reported 1,881 new coronavirus cases on Tuesday, up 81% from the previous day and the most since February 18, Read more